Urgent Call for Enhanced Breast Cancer Africa Control Measures

By Crystal Lubbe

February 19, 2025

The article from the World Health Organization (WHO) Regional Office for Africa, titled “Urgent action needed to reinforce breast cancer control measures in Africa: WHO report,” highlights critical issues and recommendations regarding breast cancer in Africa. This report brings attention to the urgent need for improved control measures to combat the rising burden of the disease across the continent.

Breast Cancer Burden

The report estimates that if current trends continue, approximately 135,000 women in sub-Saharan Africa could lose their lives to breast cancer by 2040. The WHO study assessed breast cancer control capacities in 42 out of the 47 countries in the African region. It focused on six vital areas: leadership, governance and financing, health workforce, health information systems, and service delivery. Africa faces significant gaps and disparities in breast cancer control, with critical challenges affecting prevention, diagnosis, and treatment. A severe shortage of healthcare workers limits essential services, while access to specialised cancer centers remains inadequate. Only 5 out of 47 countries have organised breast cancer screening programs, forcing most to rely on opportunistic screening. Pathology services are also insufficient, with only two countries meeting the standard of one laboratory per 100,000 people. These gaps hinder early detection and effective treatment, contributing to high mortality rates.

Drivers of Breast Cancer-Related Deaths

Late diagnoses and poor prevention efforts drive high breast cancer mortality. In 2022, Africa recorded 38 new cases and 19 deaths per 100,000 women. The report calls for urgent investments in leadership, governance, and financing to improve breast cancer care. Countries must develop and fund National Cancer Control Plans for coordinated action. Expanding oncology training is crucial to address the severe shortage of cancer professionals. Organised screening and early diagnosis programs must be accessible to all women, as early detection greatly improves survival rates. A multi-faceted approach is essential to strengthen healthcare infrastructure, train more professionals, and ensure equitable access to life-saving services.

Reference url

Recent Posts

access to medicines
         

Quantifying EU Medicine Access Challenges

🔍 Are we creating a healthcare system that truly works for everyone?

Recent findings from EFPIA shed light on alarming inequities in access to medicines across Europe, showing that only 46% of approved drugs are available to patients this year. With significant delays affecting smaller markets and critical cancer treatments, this article explores the systemic barriers at play and innovative solutions proposed to ensure fair access.

Dive into the full article to uncover how we can collectively shape a more equitable healthcare landscape.

#SyenzaNews #healthcare #MarketAccess

UK Medicine Payment Rates
      

Revitalizing Innovation: The Impact of UK Medicine Payment Rates

💡 Are the UK’s medicine payment rates stifling innovation in life sciences?

Recent analysis reveals that the staggering 23.5% payment rate for pharmaceuticals is not just limiting NHS spending but also curtailing R&D investments, delaying new drug launches, and threatening workforce stability. If we can lower these rates to below 10%, we could unleash significant growth and restore the UK’s competitive edge in the global life sciences landscape.

Discover the critical insights and recommendations that could reshape the future of healthcare in the UK.

#SyenzaNews #healthcarepolicy #innovation

Blinatumomab benefit assessment
            

Blinatumomab Benefit Assessment for ALL and Health Economics

🚀 How does a groundbreaking therapy change the landscape of acute lymphoblastic leukemia treatment?

The recent benefit assessment of Blinatumomab by the German Federal Joint Committee reveals critical insights into its potential as a consolidation therapy for adults with Philadelphia chromosome-negative B-cell precursor ALL. With its orphan drug status promising automatic benefits, the article explores the implications of its high cost and economic impacts, shedding light on the balance needed between innovation and sustainability in healthcare.

Jump into the full analysis to understand how this could impact clinical practice and health economics.

#SyenzaNews #HealthEconomics #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.